{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-134462","form_type":"8-K","ticker":"SION","cik":"0002036042","company_name":"Sionna Therapeutics, Inc.","filed_at":"2025-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.756035+00:00","generated_at":"2026-05-20T00:27:33.239851+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sionna reports positive Phase 1 data for NBD1 stabilizers SION-719 and SION-451; advances both to next trials","bullets":["Both SION-719 and SION-451 were generally well tolerated with no serious adverse events or discontinuations.","Both compounds met exposure thresholds from preclinical CFHBE model, indicating potential for clinically meaningful benefit.","SION-719 to advance to Phase 2a proof-of-concept add-on trial in CF patients; initiation H2 2025, topline mid-2026.","SION-451 to advance to Phase 1 dual combination trial with SION-2222 and SION-109; initiation H2 2025, topline mid-2026.","FDA cleared IND for SION-719; first subject dosed in midazolam drug-drug interaction study."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-134462","json":"https://secwatch.observer/filing/0001193125-25-134462.json","markdown":"https://secwatch.observer/filing/0001193125-25-134462.md","text":"https://secwatch.observer/filing/0001193125-25-134462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2036042/000119312525134462/0001193125-25-134462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2036042/000119312525134462/d944102d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T00:27:33.239851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}